PROGRAM

Bio-Neuroscience 2027

9 – 11 February 2027

Hotel Jakarta · Amsterdam

THE GLOBAL SUMMIT FOR LEADERS AND DECISION-MAKERS IN NEUROSCIENCE DRUG DEVELOPMENT

- Key Opinion Leaders
- Industry Executives
- Start-up Founders
- C-level Executives
- Investors



AN INITIATIVE OF

BROADREACH GLOBAL

CO-ORGANIZED WITH

Amsterdam Neuroscience

Day 1 Tuesday, 9 February 2027

14:00 - 14:15

Welcome to Bio-Neuroscience: Official Inauguration (15 min)

Christian J. Suojanen — Chief Executive Officer, Broadreach Global

Andrea Soto Padilla, PhD — Business Developer, Amsterdam Neuroscience

14:15 - 15:15

SESSION 1 · PANEL · 60 MIN

Addressing Rare Neurological Diseases

MODERATOR **Yael Weiss** — Founder & Chief Executive Officer, Mahzi Therapeutics

PANELISTS **Cecilia Jiménez-Mallebrera, PhD** — Group Leader, Neuromuscular Diseases Research, Hospital Sant Joan de Déu (Barcelona)

Julien de Bournet — Chief Executive Officer, As2Bio – Foundation for Angelman Syndrome Therapeutics (FAST)

Jack O'Meara — Chief Executive Officer, Aerska

Špela Miroševič, PhD — Founding President, CTNNB1 Foundation

Terry Pirovolakis — Founder & Chief Executive Officer, Elpida Therapeutics

15:15 - 16:00

SESSION 2 · PANEL · 45 MIN

Foundations & Innovative Funding Models

MODERATOR **Andrea Soto Padilla, PhD** — Business Developer, Amsterdam Neuroscience

PANELISTS **Javier García Cogorro** — Co-Founder & General Partner, Columbus Venture Partners; Founder & Member of the Board of Trustees, Fundación Columbus

David Dexter — Research Director, Parkinson's UK; Professor of Neuropharmacology, Imperial College London

Sohaib Mir — Partner, LifeArc Ventures

16:00 - 16:30

AFTERNOON NETWORKING COFFEE BREAK (30 min)

16:30 - 17:15

SESSION 3 · PANEL · 45 MIN

Innovation & Business Development Landscape

MODERATOR **Christian J. Suojanen** — Chief Executive Officer, Broadreach Global

PANELISTS **Karen LaRochelle** — Senior Vice President, Global Business Development & Strategy, Merz Therapeutics

Stephanie Leouzon — Managing Director and Vice Chair of European Healthcare Investment Banking, Stifel

17:15 - 18:00

Start-up Elevator Pitches (45 min)

18:00 - 20:00

WELCOME RECEPTION & NETWORKING

HOSTED BY MERZ THERAPEUTICS

MERZ THERAPEUTICS

Better outcomes for more patients.

Day II Wednesday, 10 February 2027

09:00 - 09:15

Opening Remarks (15 min)

Christian J. Suojanen — Chief Executive Officer, Broadreach Global

Pieter van Bokhoven — Chief Scientific Officer, Amsterdam Neuroscience IAO – VUMC

09:15 - 10:00

KEYNOTE 1 · DUAL KEYNOTE · 45 MIN

Next-Generation Brain Shuttles for ASOs, AOCs, and Complex Biologics

SPEAKERS

Robert Thorne, PhD — Denali Fellow, Denali Therapeutics

Kimberly Scearce-Levie, PhD — Chief Scientific Officer, Manifold Bio

10:00 - 10:45

SESSION 4 · PANEL · 45 MIN

BBB / Brain Shuttle Panel

MODERATOR

Stacie Weninger, PhD — Executive Director, F-Prime Biomedical Research Initiative

PANELISTS

Per-Ola Freskgård — Vice President of Science & Technology (Chief Scientific Officer), BioArctic

Arno de Wilde — Managing Director, EQT Life Sciences

Gilbert Di Paolo — Therapeutic Area Leader for Dementias, F. Hoffmann-La Roche Ltd, Pharma Research and Early Development (pRED)

James Gorman, MD, PhD — Principal Investigator, Brain Targeting Program, Wyss Institute at Harvard

10:45 - 11:15

MORNING NETWORKING COFFEE BREAK (30 min)

11:15 - 12:00

SESSION 5 · PANEL · 45 MIN

Advanced Modalities — Oligonucleotides, Splicing, and Next-Generation Medicines

MODERATOR

Pieter van Bokhoven — Chief Scientific Officer, Amsterdam Neuroscience IAO – VUMC

PANELISTS

Kasper Roet, PhD — Co-Founder & Chief Executive Officer, QurAlis

John Cox — Chief Executive Officer, Dyne Therapeutics

Steven Biesmans — Principal, UCB Ventures

Gerard Caelles — Chief Business Officer, SpliceBio

12:00 - 12:45

FIRESIDE CHAT 1 · FIRESIDE · 45 MIN

The Intra-Cellular Therapies Journey from Start-up to Acquisition (J&J, $14.6B)

MODERATOR

Kees Been — Chief Executive Officer, Kynexis Therapeutics

SPEAKER

Sharon Mates, PhD — Founder & Former Chief Executive Officer, Intra-Cellular Therapies, Inc.

12:45 - 13:45

LUNCH & NETWORKING BREAK (60 min)

HOSTED BY DANAHER

13:45 - 14:30 — **Company Presentation Session** (45 min)

14:30 - 15:15

SESSION 6 · PANEL · 45 MIN

Psychiatry's Renaissance (the Cobenfy Effect)

MODERATOR — **Andrea Soto Padilla, PhD** — Business Developer, Amsterdam Neuroscience

PANELISTS
- **Rafał Kamiński** — Chief Scientific Officer, Angelini Pharma
- **Carla Lema Tome** — Head of Neuroscience Search & Evaluation, AbbVie
- **Nick Sireau** — Co-Founder & Executive Chairman, Serenatis Bio
- **Olga Krylova** — Head of Search & Evaluation, Europe, Global Business Development & Innovation, Otsuka

15:15 - 16:00

SESSION 7 · PANEL · 45 MIN

Neuroplastogens – Rewiring Psychiatry, from Psychedelics to Next-Generation Medicines

MODERATOR — **Bruce Leuchter** — President & Chief Executive Officer, Neurvati Neurosciences

PANELISTS
- **Mark Rus** — Chief Executive Officer, Delix Therapeutics
- **Matti Karvonen** — Chief Medical Officer, Kasvu Therapeutics
- **Kabir Nath** — Chief Executive Officer, Compass Pathways
- **Lars Christian Wilde** — Co-Founder & Chief Executive Officer, Pangea Bio

16:00 - 16:30 — AFTERNOON NETWORKING COFFEE BREAK (30 min)

16:30 - 17:15

SESSION 8 · PANEL · 45 MIN

The Deal Room: From the Perspective of the CEOs

MODERATOR — **Stefan König** — Chief Executive Officer, Merz Therapeutics

PANELISTS
- **Martin Jönsson** — Former Chief Executive Officer, AlzeCure Pharma
- **Gunilla Osswald** — Chief Executive Officer, BioArctic
- **Maria Luisa Pineda** — Chief Executive Officer & Co-Founder, Envisagenics
- **Rita Balice-Gordon** — Former Chief Executive Officer, Muna Therapeutics; Board Member, Lundbeck and Collegium

17:15 - 18:00

SESSION 9 · PANEL · 45 MIN

Investing in Neuroscience Drug Development

MODERATOR — **Hakan Goker** — Managing Director, Head of Healthcare & Life Sciences, M Ventures

PANELISTS
- **Cillian King** — Partner, EQT Life Sciences
- **Claire Leurent** — Investment Director, AbbVie Ventures
- **Mathias Frederiksen** — Senior Principal, Novartis Venture Fund
- **Reetika Bhardwaj** — Principal, Dolby Family Ventures

18:00 - 20:00 — END OF DAY II & NETWORKING RECEPTION

Day III Thursday, 11 February 2027

09:00 – 09:15

Opening Remarks (15 min)

Christian J. Suojanen — Chief Executive Officer, Broadreach Global

Pieter van Bokhoven — Chief Scientific Officer, Amsterdam Neuroscience IAO – VUMC

09:15 – 10:00

KEYNOTE 2 · KEYNOTE · 45 MIN

From Inflection Point to Impact: CNS Biomarkers in Drug Development, 2027–2030

SPEAKER **Oskar Hansson, MD, PhD** — Senior Vice President, Neurodegeneration Discovery and Early Phase Clinical Development, Eli Lilly

10:00 – 10:45

SESSION 10 · PANEL · 45 MIN

Biomarker Breakthrough Year

MODERATOR **Joachim Reischl, PhD** — Vice President, External Innovation Diagnostics; Head, Neurodegenerative Franchise, Danaher

PANELISTS **Russ Lebovitz, MD, PhD** — Chief Executive Officer, Amprion

Paula Miranda — Senior Director, Pre-Clinical Translation, VectorY Therapeutics

10:45 – 11:15

MORNING NETWORKING COFFEE BREAK (30 min)

11:15 – 12:00

SESSION 11 · PANEL · 45 MIN

AI / ML in Neuroscience Drug Development

MODERATOR **Pieter van Bokhoven** — Chief Scientific Officer, Amsterdam Neuroscience IAO – VUMC

PANELISTS **Charalampos Tzoulis, MD, PhD** — Director, ICoN / Neuro-SysMed / KG Jebsen Center for PD, University of Bergen

Jeremiah Hinson, MD, PhD — Chief Scientific Officer, Neuroscience, Danaher

Dmitri Volfson — Head of Quantitative Sciences, Takeda

Parashkev Nachev, PhD — Chief Scientific Officer & Founder, Hologen; Professor of Neurology, University College London

Rob Carson — Chief Executive Officer, Vizgen

12:00 – 12:45

FIRESIDE CHAT 2 · FIRESIDE · 45 MIN

From Deal through Phase III – The Lundbeck / Longboard Pharmaceuticals Acquisition ($2.6B)

MODERATOR **Christian J. Suojanen** — Chief Executive Officer, Broadreach Global

SPEAKER **Johannes Streffer** — Senior Vice President, Global Clinical Development, Lundbeck

12:45 – 13:45

LUNCH & NETWORKING BREAK (60 min)

13:45 – 14:30

Company Presentation Session (45 min)

14:30 – 15:30

SESSION 12 · PANEL · 60 MIN

Pharma Neuroscience Priorities

MODERATOR — **Philip Scheltens, MD, PhD** — Partner & Head of the Dementia Fund, EQT Life Sciences; Professor Emeritus of Neurology, Amsterdam UMC

PANELISTS — **Richard Hargreaves** — Senior Vice President & Head of Neuroscience, Bristol Myers Squibb (BMS)

Joerg Holenz — Chief Scientific Officer, Bial

Pablo Sardi, PhD — Global Head, Neurologic and Rare Disease, Sanofi

15:30 – 16:00 — **Final Roundtable Discussion with the Audience** (30 min)

16:00 – 16:15 — **Bio-Neuroscience Awards & Closing Remarks** (15 min)

From 16:15 — END OF SUMMIT & NETWORKING RECEPTION

Bio-Neuroscience 2027

9 – 11 February 2027 · Hotel Jakarta · Amsterdam

INSIGHT - ACCESS - ENGAGEMENT - IMPACT

Thank You to Our Sponsors

OFFICIAL GOLD SPONSORS

MERZ THERAPEUTICS
Better outcomes for more patients.

danaher

OFFICIAL FOUNDING SPONSORS

EQT Life Sciences

M ventures

OFFICIAL SILVER SPONSOR

IQVIA LABORATORIES

OFFICIAL BRONZE SPONSORS

AKEURA

scantox

OFFICIAL STRATEGIC PARTNERS

WB WARMAN O'BRIEN

EFFECTIA
Consultoria Estratégica

AN INITIATIVE OF

BROADREACH GLOBAL

CO-ORGANIZED WITH

Amsterdam Neuroscience